E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Open Angle Glaucoma or Ocular Hypertension |
Glaucoma de ángulo abierto o Hipertensión ocular |
|
E.1.1.1 | Medical condition in easily understood language |
Open Angle Glaucoma or Ocular Hypertension |
Glaucoma de ángulo abierto o Hipertensión ocular |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10018307 |
E.1.2 | Term | Glaucoma and ocular hypertension |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10030348 |
E.1.2 | Term | Open angle glaucoma |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this clinical trial is to demonstrate the non-inferiority of the investigational medicinal product containing the preservative-free combination of Travoprost (40 µg/ml), Timolol (5 µg/ml) in comparison with the commercially available preservative-containing comparator Travoprost/Timolol (DuoTrav?, Alcon Laboratories Ltd., UK) in the treatment of primary open angle glaucoma or ocular hypertension by the average decrease of diurnal IOP measured between baseline and last visit. |
El objetivo principal es demostrar la no inferioridad del producto en investigación que contiene la combinación fija de Travoprost (40 µg/ml) y Timolol (5 µg/ml) sin conservantes frente al comparador comercializado de Travoprost y Timolol (DuoTrav?, Alcon Laboratories Ltd. UK) con conservante, en el tratamiento del glaucoma primario de ángulo abierto o de la hipertensión ocular mediante la disminución media de la PIO diurna medida entre la visita basal y la última visita. |
|
E.2.2 | Secondary objectives of the trial |
Secondary efficacy objectives are the average decreases of diurnal IOP measured between baseline and days 7 and 14 and the proportion of patients with measured IOP <21 mmHg at the end of the clinical trial. |
Los objetivos secundarios de eficacia son los descensos medios de la PIO diurna medidos entre el momento basal y los días 7 y 14 y el porcentaje de paciente con una determinación de PIO <21 mm Hg al final del ensayo clínico. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
? male or female patients, of any race and ?18 years of age; ? diagnosed of unilateral or bilateral primary open angle glaucoma or ocular hypertension; ? on treatment with an IOP-lowering prostaglandin analogue/beta blocker combination for at least 6 months; ? on treatment with an IOP ?21 mmHg on medication measured as a mean of both eyes at two measurements at least one hour apart; ? best-corrected visual acuity ?20 of 100 corresponding to logMAR of 0.7 in both eyes; ? in case of women, postmenopausal (>12 months without menstrual bleeding), surgically sterilized, or on use of effective birth control measures; ? expected by the investigator that IOP would remain controlled with the new treatment without optic nerve damage or progression of visual field loss; ? able to understand the requirements of the clinical trial and to agree to return for required follow-up visits; ? willing to provide voluntary written informed consent and data protection declaration before any clinical trial related procedure is performed. |
? pacientes hombres o mujeres, de cualquier raza y ?18 años; ? que estén diagnosticados de glaucoma primario de ángulo abierto o hipertensión ocular; ? que estén en tratamiento con una combinación de un reductor de la PIO análogo de prostaglandina y un bloqueante beta durante al menos 6 meses; ? que estén en tratamiento con una PIO ?21 mmHg, determinada como la media de ambos ojos en dos mediciones realizadas al menos con una hora de diferencia; ? mejor agudeza visual corregida ?20 de 100 que corresponde a logMAR de 0,7 en ambos ojos ? en el caso de las mujeres, que sean posmenopáusicas (>12 meses sin periodo), estén esterilizadas quirúrgicamente o usen medidas anticonceptivas eficaces; ? en los que el investigador prevea que la PIO permanecerá controlada con el nuevo tratamiento sin dañar el nervio óptico y sin que avance la pérdida del campo visual; ? capaces de entender los requisitos del ensayo clínico y que estén dispuestos a acudir a las visitas de control necesarias; ? dispuestos a otorgar voluntariamente su consentimiento informado por escrito y a firmar la declaración de protección de datos antes de realizar cualquier procedimiento relacionado con el ensayo. |
|
E.4 | Principal exclusion criteria |
? pre-treatment for primary open angle glaucoma or intraocular hypertension other than prostaglandin analogue/beta blocker combinations; ? a history of chronic or recurrent inflammatory eye disease, ocular trauma or infections; ? narrow-angle/angle-closure glaucoma; ? clinically significant or progressive retinal disease; ? intraocular surgery within the past 6 months; ? ocular laser surgery within the past 3 months; ? a change in glaucoma therapy within 1 month before the screening visit; ? best-corrected visual acuity worse than 0.7 logarithm of minimal angle of resolution (logMAR) score, extremely narrow or partially closed angle, cup/disk ratio >0.8; ? history of bronchial asthma, or severe chronic obstructive pulmonary disease; reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease. ? treatment with local or systemic corticosteroids; ? inability to discontinue the use of glucocorticoid medications; ? not receiving stable doses of any medication that could affect IOP for 30 days before the beginning of the clinical trial (e.g. clonidine); ? a history of allergic hypersensitivity or poor tolerance to any component of the eye drop solution used in this clinical trial or a contraindication of ß-adrenergic receptor antagonists due to systemic disease; ? sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock ? pregnancy or breast-feeding or childbearing potential not protected by a highly effective contraceptive method of birth control; ? current participation or not yet completed period of at least 30 days since ending other investigational device or drug trial(s); ? unwillingness or inability to comply with the clinical trial procedures; ? unwillingness to consent to storage and saving and transmission of pseudonymous medical data for clinical trial reasons; ? who are legally incapacitated, ? who are legally detained in an official institute. |
? tratamiento previo para el glaucoma primario de ángulo abierto o hipertensión intraocular que no sea con un análogo de prostaglandina y un bloqueante beta ? antecedentes de enfermedad inflamatoria ocular crónica o recurrente, traumatismos o infecciones oculares; ? glaucoma de ángulo estrecho o ángulo cerrado; ? retinopatía clínicamente importante o progresiva; ? cirugía intraocular en los 6 últimos meses; ? cirugía ocular con láser en los 3 últimos meses; ? cambio en el tratamiento del glaucoma en el mes anterior a la visita de selección; ? mejor agudeza visual corregida inferior a 0,7 logaritmo del ángulo mínimo de resolución (logMAR), ángulo muy estrecho o parcialmente cerrado, relación copa/disco >0,8; ? antecedentes de asma bronquial o enfermedad pulmonar obstructiva crónica grave; enfermedad reactiva de las vías respiratorias. ? tratamiento con corticosteroides locales o sistémicos; ? incapacidad para suspender el uso de glucocorticoides; ? dosis inestables de algún medicamento que pudiera afectar a la PIO en los 30 días anteriores al inicio del ensayo clínico (p. ej., clonidina); ? antecedentes de hipersensibilidad alérgica o mala tolerancia a cualquier componente de la solución en colirio usada en este ensayo clínico o contraindicación de los antagonistas de los receptores adrenérgicos ß por enfermedad sistémica; ? bradicardia sinusal, bloqueo auriculoventricular de segundo o tercer grado, insuficiencia cardiaca franca o choque cardiogénico; ? embarazo o lactancia o edad fértil sin protección mediante un método anticonceptivo eficaz; ? participación actual o que no haya terminado todavía el periodo de al menos 30 días desde la finalización de la participación en otro(s) ensayo(s) clínico(s) de un fármaco o dispositivo en investigación ? poca disposición o incapacidad para completar los procedimientos del ensayo clínico; ? poca disposición a otorgar el consentimiento para la conservación, grabación y transmisión de los datos médicos bajo pseudónimo por razones del ensayo clínico; ? incapacidad legal, ? detenidos legalmente en una institución oficial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To demonstrate the non-inferiority of the investigational medicinal product containing the preservative-free combination of Travoprost (40 µg/ml), Timolol (5 µg/ml) in comparison with the commercially available preservative-containing comparator Travoprost/Timolol (DuoTrav?, Alcon Laboratories Ltd., UK) in the treatment of primary open angle glaucoma or ocular hypertension by the average decrease of diurnal IOP measured between baseline and last visit. |
Demostrar la no inferioridad del producto en investigación que contiene la combinación fija de Travoprost (40 µg/ml) y Timolol (5 µg/ml) sin conservantes frente al comparador comercializado de Travoprost y Timolol (DuoTrav?, Alcon Laboratories Ltd. UK) con conservante, en el tratamiento del glaucoma primario de ángulo abierto o de la hipertensión ocular mediante la disminución media de la PIO diurna medida entre la visita basal y la última visita. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The average decreases of diurnal IOP measured between baseline and days 7 and 14 and the proportion of patients with measured IOP <21 mmHg at the end of the clinical trial. |
Descensos medios de la PIO diurna medidos entre el momento basal y los días 7 y 14 y el porcentaje de paciente con una determinación de PIO <21 mm Hg al final del ensayo clínico. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
enmascarado para el evaluador |
Observer-blind |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last patient |
Ultima visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |